How I treat extramedullary myeloma
How I treat extramedullary myeloma
复制标题
DOI：
10.1182/blood-2015-07-635383
复制
发表时间：
2016-02-25
期刊：
影响因子：
20.3
通讯作者：
Moreau, Philippe
中科院分区：
文献类型：
--
作者：
Touzeau, Cyrille;Moreau, Philippe
髓外骨髓瘤（EMM）是指多发性骨髓瘤（MM）患者骨髓外存在浆细胞（PC）。使用敏感的成像技术，包括磁共振成像和正电子发射断层扫描/计算机断层扫描，EMM可能会发现在整个疾病过程中的MM患者高达30%。骨髓外的PC的造血传播的分子机制仅部分已知，涉及缺氧和粘附分子的表达改变。髓外疾病与不良预后因素（即，高乳酸脱氢酶水平、17 p缺失和高危基因表达谱）相关。EMM的预后很差，髓外复发患者的中位总生存期为
Extramedullary myeloma (EMM) is defined by the presence of plasma cells (PCs) outside the bone marrow in a patient with multiple myeloma (MM). Using sensitive imaging techniques including magnetic resonance imaging and positron emission tomography/computed tomography, EMM may be found in up to 30% of MM patients across the overall disease course. The molecular mechanisms underlying the hematogenous spread of PCs outside the bone marrow are only partially known and involve hypoxia and an altered expression of adhesion molecules. Extramedullary disease is associated with adverse prognostic factors (ie, high lactate dehydrogenase level, 17p deletion, and high-risk gene expression profile). The prognosis of EMM is poor, and the median overall survival of patients who experience an extramedullary relapse is